Healthcare Equipment and Supplies
Company Overview of Xagenic Inc.
Xagenic Inc. is a molecular diagnostics company that offers a lab-free molecular diagnostic platform that enables clinicians for on-demand near patient molecular testing to make treatment decisions for their patients at the time of first consultation. It offers Xagenic X1, a testing system that automates all laboratory processes with single use cartridges to allow diagnostic assays to be performed by users without any training in laboratory techniques. The company was founded in 2010 and is based in Toronto, Canada with an additional office in San Francisco.
55 York Street
Toronto, ON M5J 1R7
Founded in 2010
Key Executives for Xagenic Inc.
Founder, Chief Executive Officer and Director
Vice President of Business Development
Compensation as of Fiscal Year 2016.
Xagenic Inc. Key Developments
Xagenic Announces Successful Testing of Beta X1 System
Nov 10 16
Xagenic Inc. reported that the Beta version of its fully automated X1TM molecular diagnostic testing system has undergone successful testing at an external clinical site. The first assay developed for the system is a combined chlamydia and gonorrhoea (CT/NG) test that is designed to facilitate screening, diagnosis and rapid treatment of these sexually-transmitted diseases. The X1 system is intended for physician office use, with minimal hands on time (< 1 minute) needed to run a test, and a definitive test result is generated within a typical office consult. The external study confirmed the feasibility of point-of-care testing using the X1 system, and that the X1 CT/NG test was able to generate testing results comparable to gold-standard molecular tests run at centralized labs. The X1 testing system automates all aspects of sample processing and analysis. A user introduces a sample into the disposable cartridge, inserts the cartridge into the testing system and starts a test. No incubation or sample extraction steps are required. Use of the system by clinical personnel was shown to be straightforward during the recent study, and very low rates of user errors were observed. The Xagenic AuRATM technology is a unique direct detection approach that leverages electrochemical signal amplification to eliminate the need for enzymatic amplification.
Xagenic Inc. Presents at Canaccord Genuity 2015 Medical Technology & Diagnostics Forum, Nov-19-2015 10:00 AM
Oct 31 15
Xagenic Inc. Presents at Canaccord Genuity 2015 Medical Technology & Diagnostics Forum, Nov-19-2015 10:00 AM. Venue: Westin Grand Central, New York, New York, United States. Speakers: Ihor Boszko, Vice President of Business Development, Timothy I. Still, Chief Executive Officer, President and Director.
Xagenic Appoints Randall Wilhoite as Vice President of Operations
Aug 25 15
Xagenic announced that Randall Wilhoite has joined the company as Vice President of Operations. Wilhoite will oversee manufacturing and operations to ensure the company’s commercial objectives for the Xagenic X1 platform are met. Wilhoite brings a wealth of operational experience in vitro diagnostics to this newly-established role at Xagenic, most recently from Siemens Healthcare Diagnostics, where he directed point of care manufacturing. Prior to Siemens, Wilhoite held senior operations, logistics and supply chain roles at two companies – Oscient Pharmaceuticals Inc. and Anika Therapeutics Inc. He began his career in the diagnostics division of Abbott Laboratories Inc., where he spent 15 years in various roles within operations and received several awards for improved efficiency and cost reduction.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries